These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 28063135)

  • 1. Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.
    Ericsson Å; Lundqvist A
    Appl Health Econ Health Policy; 2017 Apr; 15(2):237-248. PubMed ID: 28063135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.
    Davies MJ; Glah D; Chubb B; Konidaris G; McEwan P
    Pharmacoeconomics; 2016 Sep; 34(9):953-66. PubMed ID: 27438706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
    Dempsey M; Mocarski M; Langer J; Hunt B
    Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting.
    Drummond R; Malkin S; Du Preez M; Lee XY; Hunt B
    Diabetes Obes Metab; 2018 Oct; 20(10):2371-2378. PubMed ID: 29797389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.
    Dempsey M; Mocarski M; Langer J; Hunt B
    J Med Econ; 2018 Nov; 21(11):1110-1118. PubMed ID: 30114954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
    Hunt B; Mocarski M; Valentine WJ; Langer J
    J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
    Cannon AJ; Bargiota A; Billings L; Hunt B; Leiter LA; Malkin S; Mocarski M; Ranthe MF; Schiffman A; Doshi A
    J Manag Care Spec Pharm; 2020 Feb; 26(2):143-153. PubMed ID: 31856636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.
    Raya PM; Blasco FJA; Hunt B; Martin V; Thorsted BL; Basse A; Price H
    Diabetes Obes Metab; 2019 Jun; 21(6):1349-1356. PubMed ID: 30740861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
    Evans M; Billings LK; Håkan-Bloch J; Slothuus U; Abrahamsen TJ; Andersen A; Jansen JP
    J Med Econ; 2018 Apr; 21(4):340-347. PubMed ID: 29164973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.
    Hunt B; Mocarski M; Valentine WJ; Langer J
    Adv Ther; 2017 Apr; 34(4):954-965. PubMed ID: 28281218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.
    Aroda VR; González-Galvez G; Grøn R; Halladin N; Haluzík M; Jermendy G; Kok A; Őrsy P; Sabbah M; Sesti G; Silver R
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):596-605. PubMed ID: 31189519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
    Jendle J; Ericsson Å; Ekman B; Sjöberg S; Gundgaard J; da Rocha Fernandes J; Mårdby AC; Hunt B; Malkin SJP; Thunander M
    J Med Econ; 2020 Nov; 23(11):1311-1320. PubMed ID: 32746676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.
    Kaku K; Araki E; Tanizawa Y; Ross Agner B; Nishida T; Ranthe M; Inagaki N
    Diabetes Obes Metab; 2019 Dec; 21(12):2674-2683. PubMed ID: 31407845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.
    Watada H; Kaneko S; Komatsu M; Agner BR; Nishida T; Ranthe M; Nakamura J
    Diabetes Obes Metab; 2019 Dec; 21(12):2694-2703. PubMed ID: 31423685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.
    Ericsson Å; Glah D; Lorenzi M; Jansen JP; Fridhammar A
    PLoS One; 2018; 13(2):e0191953. PubMed ID: 29408938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.
    Vilsbøll T; Vora J; Jarlov H; Kvist K; Blonde L
    Clin Drug Investig; 2016 Apr; 36(4):293-303. PubMed ID: 26894800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.
    Vilsbøll T; Blevins TC; Jodar E; Poulter N; Tentolouris N; Ross Agner BF; Lehmann L; Leiter LA
    Diabetes Obes Metab; 2019 Jun; 21(6):1506-1512. PubMed ID: 30785655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
    Ridderstråle M; Jensen MM; Gjesing RP; Niskanen L
    J Med Econ; 2013; 16(4):468-78. PubMed ID: 23384160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.